Significantly higher KRAS MAF levels were detected in patients with G2 tumor grading, liver metastasis, and in those who did not undergo surgery at site of primary tumor; as for NRAS, significantly higher levels were found in patients with mucinous adenocarcinoma or with lung metastasis. The gene discussed is KRAS; the disease is mucinous adenocarcinoma.